All times listed are Central Daylight Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.
Seminar Presenter: Peter Grayson, MD, MSc – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Seminar Presenter: Peter Grayson, MD, MSc – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
0853: Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status
Location: W375D-E
Presenting Author: Philip Carlucci, MD – New York University School of Medicine
CE: 0.00
9:15 AM - 9:30 AM Central Time
0854: The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study
0893: Transcriptomic insights into GCA compared to clinically diverse controls: Inflammation, Aging, Therapeutic Targets and the role of SPP1 in the temporal artery
0880: Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
0881: Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
0882: Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study
Location: S102
Presenting Author: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
CE: 0.00
11:00 AM - 11:15 AM Central Time
0883: Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
Abstract Moderator: Alexis Ogdie, MD – University of Pennsylvania
Abstract Moderator: Soumya Reddy, MD – NYU Grossman School of Medicine
CE: 0.00
10:00 AM - 11:30 AM Central Time
27M18: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies
Location: W196A-C
Abstract Moderator: Alexis Ogdie, MD – University of Pennsylvania
Abstract Moderator: Soumya Reddy, MD – NYU Grossman School of Medicine
CE: 0.00
10:00 AM - 10:15 AM Central Time
0873: Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
0874: Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Location: W196A-C
Presenting Author: Atul Deodhar, MD – Oregon Health & Science University
CE: 0.00
10:30 AM - 10:45 AM Central Time
0875: Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Location: W196A-C
Presenting Author: Joseph F. Merola, MD, MMSc – Department of Dermatology and Department of Medicine, UT Southwestern Medical Center
CE: 0.00
10:45 AM - 11:00 AM Central Time
0876: Effect of QX002N on Clinical and Radiographic Outcomes in Ankylosing Spondylitis: Results from a Phase III Randomized, Double-blind, Placebo-Controlled Study
Location: W196A-C
Presenting Author: Xiaofeng Zeng, MD – Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID)
CE: 0.00
11:00 AM - 11:15 AM Central Time
0877: Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
0871: The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes
Location: S105
Presenting Author: Renuka Nayak, MD, PhD – University of California, San Francisco (UCSF)
CE: 0.00
11:15 AM - 11:30 AM Central Time
0872: Silencing of Schnurri-3 protects from TNF-induced bone loss and is accompanied by upregulation of type I Interferon-Stimulated Genes (ISGs) in osteoblasts.
Alternate Moderator: Deepali Sen, MBBS – Washington University in St Louis
CE: 0.00
10:00 AM - 10:15 AM Central Time
0861: Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Location: W190A-B
Presenting Author: Xueting Yuan, MD – Peking Union Medical College Hoapital
CE: 0.00
10:15 AM - 10:30 AM Central Time
0862: In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
0863: Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
Location: W190A-B
Presenting Author: Raphael Kirou, BSc – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
CE: 0.00
10:45 AM - 11:00 AM Central Time
0864: Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
Location: W190A-B
Presenting Author: Danica Lee, BA – University of Pittsburgh School of Medicine
CE: 0.00
11:00 AM - 11:15 AM Central Time
0865: Spatial Transcriptomic Analysis of Calcinosis Cutis in Dermatomyositis Uncovers Disease-Associated Pathways Involving IL-6, Tissue Remodeling, and Osteopontin
Abstract Moderator: Jane Salmon, MD – Hospital for Special Surgery
CE: 0.00
10:00 AM - 10:15 AM Central Time
0855: Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Location: W192A-C
Presenting Author: Jane Salmon, MD – Hospital for Special Surgery
CE: 0.00
10:15 AM - 10:30 AM Central Time
0856: Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
0858: IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
Location: W192A-C
Presenting Author: Kavya Sugur, PhD – Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor
CE: 0.00
11:00 AM - 11:15 AM Central Time
0859: Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
0860: Activated Protein C Resistance and Protein C Antibodies in the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository
The Role of the Mammalian Commensal Intestinal Microbiota in Intestinal and Systemic Immunity Affecting the Development and Mitigation of Ocular Inflammation
0913: Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
0906: Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
0926: Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Location: Hall F1
Abstract Poster Presenter: Minyun Zhou, PhD – Simcere Pharmaceutical Group
CE: 0.00
10:30 AM - 12:30 PM Central Time
0924: Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology
Location: Hall F1
Abstract Poster Presenter: Lauren Klingemann, BS – University of Nebraska Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
0920: Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Location: Hall F1
Abstract Poster Presenter: Elizabeth Morgan, BS – Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH
CE: 0.00
10:30 AM - 12:30 PM Central Time
0929: SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
0933: Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Location: Hall F1
Abstract Poster Presenter: Yunwei Xia, BA – Feinstein Institutes for Medical Research
CE: 0.00
10:30 AM - 12:30 PM Central Time
0930: Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Ryan Camire, PhD – Kymera Therapeutics
CE: 0.00
10:30 AM - 12:30 PM Central Time
0928: Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
0918: Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Location: Hall F1
Abstract Poster Presenter: Anthony Cruz, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH
CE: 0.00
10:30 AM - 12:30 PM Central Time
0932: Compartment-specific NK-cell phenotypes reveal distinct maturation and activation states in inflammatory arthritis
Location: Hall F1
Abstract Poster Presenter: Wolfgang Merkt, MD – University Hospital Düsseldorf
CE: 0.00
10:30 AM - 12:30 PM Central Time
0925: Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
0919: Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
0921: Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Location: Hall F1
Abstract Poster Presenter: Hannah Johnson, BS – University of Nebraska Medical Center
(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I
CE: 0.00
10:30 AM - 12:30 PM Central Time
Systemic Sclerosis & Related Disorders – Basic Science Poster I
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
0955: Surveying RNA methylation in scleroderma highlights roles for demethylases ALKBH5 and FTO in fibrosis
Location: Hall F1
Abstract Poster Presenter: Alexander Cai, BS – University of Michigan
CE: 0.00
10:30 AM - 12:30 PM Central Time
0956: Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics
Location: Hall F1
Abstract Poster Presenter: Alexandru-Emil Matei, MD – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University
CE: 0.00
10:30 AM - 12:30 PM Central Time
0957: Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc
Location: Hall F1
Abstract Poster Presenter: Astrid Hofman, MSc – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich
CE: 0.00
10:30 AM - 12:30 PM Central Time
0958: Asynchronous Resolution of Inflammation and Fibrosis in a Prolonged Experimental Model Suggests Distinct Temporal Dynamics and Resolution Mechanisms in Systemic Sclerosis
0959: Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
0960: Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
CE: 0.00
10:30 AM - 12:30 PM Central Time
0961: Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
CE: 0.00
10:30 AM - 12:30 PM Central Time
0962: Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Location: Hall F1
Abstract Poster Presenter: Dennis Bleck, PhD (he/him/his) – University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
0964: A Single-cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-specific Pathways in Autoimmune Disorders
Location: Hall F1
Abstract Poster Presenter: Jinyi Qian, -None- – Shanghai Jiao Tong University School of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
0965: Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
0966: Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
0973: Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.
Location: Hall F1
Abstract Poster Presenter: Takuya Kotani, MD, PhD – Osaka Medical and Pharmaceutical University
CE: 0.00
10:30 AM - 12:30 PM Central Time
0974: Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
CE: 0.00
10:30 AM - 12:30 PM Central Time
0975: Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
CE: 0.00
10:30 AM - 12:30 PM Central Time
0976: LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
0977: The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Yun Zhang, PhD – University Hospital Erlangen
CE: 0.00
10:30 AM - 12:30 PM Central Time
0963: Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
Location: Hall F1
Abstract Poster Presenter: Emanuele Gotelli, MD, PhD – Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova
CE: 0.00
10:30 AM - 12:30 PM Central Time
(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
CE: 0.00
10:30 AM - 12:30 PM Central Time
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
0978: IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis.
0982: Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
CE: 0.00
10:30 AM - 12:30 PM Central Time
0983: Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
0987: S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
0990: An Fc-engineered Agonistic anti-pd-1 Antibody Selectively Depletes pd-1+ Cells and Attenuates T Cell Activation in vitro and in vivo in a Xenogeneic Graft-versus-host Disease (GvHD) Model
0991: MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Laura McMillan – Sitryx Therapeutics
CE: 0.00
10:30 AM - 12:30 PM Central Time
0992: FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
0993: NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Location: Hall F1
Abstract Poster Presenter: Leah Huey, BS – Oregon Health & Science University
CE: 0.00
10:30 AM - 12:30 PM Central Time
0994: UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
Location: Hall F1
Abstract Poster Presenter: Lin Yang, PhD – PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China; PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China; Cyrus Tang Medical Institute, Soochow University, Suzhou, Jiangsu, China
CE: 0.00
10:30 AM - 12:30 PM Central Time
0995: Resident Memory T Cells Stimulate Pathogenic Activity in Fibroblast-like Synoviocytes
Location: Hall F1
Abstract Poster Presenter: Madison Mangin, BS – Boston Children's Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
0996: Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
1000: A Deep-learning Based Approach Uncovers Novel Mediators of Micro-rna Restraint of type-2 Immunity
Location: Hall F1
Abstract Poster Presenter: Shaan Sekhon, BA – CNU College of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1001: LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Location: Hall F1
Abstract Poster Presenter: Xiao Huang, MS – Leads Biolabs
CE: 0.00
10:30 AM - 12:30 PM Central Time
1002: ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells
Location: Hall F1
Abstract Poster Presenter: Xiao Zhang, n/a – The Eighth Affiliated Hospital of Sun Yat-sen University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1003: Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Location: Hall F1
Abstract Poster Presenter: Yan Zhang, PhD – Capstan Therapeutics
CE: 0.00
10:30 AM - 12:30 PM Central Time
1004: Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Location: Hall F1
Abstract Poster Presenter: Yang Yang, PhD – Boston Children's Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1005: CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
1008: Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Location: Hall F1
Abstract Poster Presenter: Ahmet Gül, MD – Istanbul University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1009: Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
1010: Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review
1011: Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Location: Hall F1
Abstract Poster Presenter: Ethan Eickmann, BA – Brigham and Women's Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1012: Racial and Gender Disparities in Gout Clinical Trials
1017: Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
1018: Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
1019: Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
CE: 0.00
10:30 AM - 12:30 PM Central Time
1020: Cohort Study of European Ancestry, Geographic Region, Ambient Ultraviolet Irradiance and the Risk of Developing Polymyalgia Rheumatica among Women
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
CE: 0.00
10:30 AM - 12:30 PM Central Time
1021: Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
1027: GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
1028: Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
1031: Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Location: Hall F1
Abstract Poster Presenter: Satani Sharkas, MD – Boston Medical Center - Brighton
CE: 0.00
10:30 AM - 12:30 PM Central Time
1032: Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Location: Hall F1
Abstract Poster Presenter: Sharan Rai, PhD – Massachusetts General Hospital/Harvard Medical School
CE: 0.00
10:30 AM - 12:30 PM Central Time
1033: Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
1035: Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center
1050: Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1052: “prednisone… a Necessary Evil…” Developing an Evidence-based Benefits vs. Harms Shared Decision-making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1054: Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Location: Hall F1
Abstract Poster Presenter: Ye Liu, MD, MPH, DrPH – University of Alabama at Birmingham
CE: 0.00
10:30 AM - 12:30 PM Central Time
1045: Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
1044: Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
1043: The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
Location: Hall F1
Abstract Poster Presenter: Gordon Lam, MD, FACR – Arthritis & Osteoporosis Consultants of the Carolinas
CE: 0.00
10:30 AM - 12:30 PM Central Time
1047: Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Location: Hall F1
Abstract Poster Presenter: Jon Golenbiewski, DO – Wake Forest University School of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1041: Associated Factors and Direct Cost Analysis of Dose Reduction and Discontinuation of Biological Therapies in Rheumatoid Arthritis and Spondyloarthritis: Findings from a Colombian Cohort Within the Framework of an Integrated Management Model
1042: Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Location: Hall F1
Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
CE: 0.00
10:30 AM - 12:30 PM Central Time
(1055–1087) Healthcare Disparities in Rheumatology Posters
CE: 0.00
10:30 AM - 12:30 PM Central Time
Healthcare Disparities in Rheumatology
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
1057: Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
1083: How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
1067: Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
1066: Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
CE: 0.00
10:30 AM - 12:30 PM Central Time
1077: Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
1073: Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases
1062: Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
1068: Association Between Social Determinants of Health Domains and covid-19-related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data
1087: Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Zoe Reed, MPH – Oklahoma Medical Research Foundation
CE: 0.00
10:30 AM - 12:30 PM Central Time
1069: Strengthening Rheumatology Workforce Capacity and Impact on Patient Care in Louisiana: Expanding Fellowship Training Opportunities Through Strategic Partnerships
1063: Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Location: Hall F1
Abstract Poster Presenter: Farheen Malik, MD – Jacobi Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1074: Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
1061: Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
(1088–1122) Immunological Complications of Medical Therapy Poster
CE: 0.00
10:30 AM - 12:30 PM Central Time
Immunological Complications of Medical Therapy Poster
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
1088: Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
CE: 0.00
10:30 AM - 12:30 PM Central Time
1089: Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
CE: 0.00
10:30 AM - 12:30 PM Central Time
1090: Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
1092: Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Location: Hall F1
Abstract Poster Presenter: Binod Kc, MBBS – SUNY Upstate Medical University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1093: Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Blake Baay, BS – UT Southwestern
CE: 0.00
10:30 AM - 12:30 PM Central Time
1094: Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
CE: 0.00
10:30 AM - 12:30 PM Central Time
1095: Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
1096: Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.
Location: Hall F1
Abstract Poster Presenter: Elisabet Perea-Martínez, MD – Rheumatology section, Hospital General Universitario de Elda
CE: 0.00
10:30 AM - 12:30 PM Central Time
1097: Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
CE: 0.00
10:30 AM - 12:30 PM Central Time
1098: Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Location: Hall F1
Abstract Poster Presenter: Francisco Arias, MD – University of Texas Rio Grande Valley
CE: 0.00
10:30 AM - 12:30 PM Central Time
1099: Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Location: Hall F1
Abstract Poster Presenter: Grace Haeun Lee, BA – Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1100: Associations Between Pre-existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
1102: Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Location: Hall F1
Abstract Poster Presenter: Julia Barasch, MD – Weill Cornell - New York Presbyterian
CE: 0.00
10:30 AM - 12:30 PM Central Time
1103: Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Kayla Chubbs, MD – Dalhousie University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1104: Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
CE: 0.00
10:30 AM - 12:30 PM Central Time
1105: Association Between Pre-existing Rheumatoid Arthritis and Immune-related Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
CE: 0.00
10:30 AM - 12:30 PM Central Time
1106: Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Location: Hall F1
Abstract Poster Presenter: KO JEN LEE, MD, PhD – National Taiwan University Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1107: Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1108: Baseline Features, Immunosuppression, and Immune-related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1109: Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
1113: Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Location: Hall F1
Abstract Poster Presenter: Qi Wang, MD – Metrohealth System/Case Western Reserve University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1114: Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Location: Hall F1
Abstract Poster Presenter: Qiang Xu, n/a – Guangzhou University of Traditional Chinese Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1115: Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Location: Hall F1
Abstract Poster Presenter: Samuel Bitoun, MD, PhD – Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184
CE: 0.00
10:30 AM - 12:30 PM Central Time
1116: Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
1118: Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
1120: Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Location: Hall F1
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
CE: 0.00
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1122: A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-related Problems
1123: Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Location: Hall F1
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
CE: 0.00
10:30 AM - 12:30 PM Central Time
1126: Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
1140: PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs
Location: Hall F1
Abstract Poster Presenter: Sadiq Umar, PhD – University of Illinois at Chicago
CE: 0.00
10:30 AM - 12:30 PM Central Time
1129: Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
1130: Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Location: Hall F1
Abstract Poster Presenter: Kiara Tan, BA – Massachusetts General Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1137: Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
1127: The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
1136: The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
1149: Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
1153: New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
1154: Assessment of Damage Using the igg4-related Disease Damage Index
Location: Hall F1
Abstract Poster Presenter: Eduardo Martin-Nares, MD, MSc – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
CE: 0.00
10:30 AM - 12:30 PM Central Time
1155: Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
1157: Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Location: Hall F1
Abstract Poster Presenter: Ella Steiner, -None- – Ruhr-University Bochum, Germany
CE: 0.00
10:30 AM - 12:30 PM Central Time
1158: Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Location: Hall F1
Abstract Poster Presenter: guishan liu, PA – Peking Union Medical College Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1159: IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
CE: 0.00
10:30 AM - 12:30 PM Central Time
1163: Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
Location: Hall F1
Abstract Poster Presenter: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
CE: 0.00
10:30 AM - 12:30 PM Central Time
1164: Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients
1165: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
Location: Hall F1
Abstract Poster Presenter: Joseph F. Merola, MD, MMSc – Department of Dermatology and Department of Medicine, UT Southwestern Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1166: Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis
1167: Clinical Characteristics and Outcomes of igg4-related Disease Patients Who Chose Watchful Observation Without Treatment Intervention: A Single-center Study
Location: Hall F1
Abstract Poster Presenter: Kanako Chujo, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1168: Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
1175: Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Location: Hall F1
Abstract Poster Presenter: Nils Venhoff, MD – Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg
CE: 0.00
10:30 AM - 12:30 PM Central Time
1176: VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
1186: Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
1187: Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Tulaton Sodsri, MD – Texas Tech University Health Sciences Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1188: Aortic Wall Shear Stress May Be a Protective Factor Against Development of Spinal Osteoproliferation
Location: Hall F1
Abstract Poster Presenter: Umut Kalyoncu, n/a – Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
CE: 0.00
10:30 AM - 12:30 PM Central Time
1189: Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
1192: Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Location: Hall F1
Abstract Poster Presenter: ANA PAULA LUPPINO-ASSAD, MD, PhD – Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP)
CE: 0.00
10:30 AM - 12:30 PM Central Time
1193: Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Location: Hall F1
Abstract Poster Presenter: Angela Chang, MD – University of British Columbia
CE: 0.00
10:30 AM - 12:30 PM Central Time
1194: Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
1198: Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
1201: Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Irada Choudhuri, MD – University of Pittsburgh Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1202: High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Location: Hall F1
Abstract Poster Presenter: Iris Tang, MBBS,MRCP – Department of Medicine, LKS Faculty of Medicine, University of Hong Kong
CE: 0.00
10:30 AM - 12:30 PM Central Time
1203: Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis - A Case Series
1205: Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
CE: 0.00
10:30 AM - 12:30 PM Central Time
1206: Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
CE: 0.00
10:30 AM - 12:30 PM Central Time
1207: Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jesus Valencia, MD – Johns Hopkins Bayview Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1208: Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
CE: 0.00
10:30 AM - 12:30 PM Central Time
1209: Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
CE: 0.00
10:30 AM - 12:30 PM Central Time
1210: Artificial Intelligence-based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the Capiami Cohort
1211: Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Location: Hall F1
Abstract Poster Presenter: Kristina Svobodová, MD (she/her/hers) – Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1212: Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Location: Hall F1
Abstract Poster Presenter: Maria Rosa Pellico, MD – ASST Pini-CTO, Clinical Rheumatology Unit
CE: 0.00
10:30 AM - 12:30 PM Central Time
1213: Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
1220: Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Location: Hall F1
Abstract Poster Presenter: Wei Bian, MD – Tianjin Medical University
CE: 0.00
10:30 AM - 12:30 PM Central Time
(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster
CE: 0.00
10:30 AM - 12:30 PM Central Time
Pain in Rheumatic Disease Including Fibromyalgia Poster
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
1243: Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
Location: Hall F1
Abstract Poster Presenter: Robert Katz, MD – Rush University Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1228: Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Location: Hall F1
Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
CE: 0.00
10:30 AM - 12:30 PM Central Time
1237: Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
1246: Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial
Location: Hall F1
Abstract Poster Presenter: seda yildiz, MD – izmir sehir hastanesi
CE: 0.00
10:30 AM - 12:30 PM Central Time
1222: Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Ahmed Abouelella, MBBCH – College of Human Medicine, Benha University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1229: Extent versus impact: Sex-specific burden of chronic pain in older adults
1236: Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Location: Hall F1
Abstract Poster Presenter: Michael Kaplan, MD – Icahn School of Medicine at Mount Sinai
CE: 0.00
10:30 AM - 12:30 PM Central Time
1245: Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
Location: Hall F1
Abstract Poster Presenter: Rubab Rizwan, MD – VBMC,Nuvance Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1231: TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
1252: Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
Location: Hall F1
Abstract Poster Presenter: Melissa Mannion, MD – University of Alabama at Birmingham
CE: 0.00
10:30 AM - 12:30 PM Central Time
1253: Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Location: Hall F1
Abstract Poster Presenter: Nisha Sapkota, MD – One Brooklyn Health- Interfaith Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1254: Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
1264: Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
1266: Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
1267: Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Location: Hall F1
Abstract Poster Presenter: Leah Santacroce, MS – Brigham and Women's Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1268: Development of the LupusCoach Chatbot: Results of a Focus Group
1277: Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama Birmingham
CE: 0.00
10:30 AM - 12:30 PM Central Time
1278: Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Location: Hall F1
Abstract Poster Presenter: Emily Masi, MD, PhD – Cohen Children's Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1279: Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Location: Hall F1
Abstract Poster Presenter: Reagan Reid, MSc – University of Toronto
CE: 0.00
10:30 AM - 12:30 PM Central Time
1280: Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
1287: A Clear Pattern of Clinical Presentation in Juvenile Systemic Scleroderma Is Associated with Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
CE: 0.00
10:30 AM - 12:30 PM Central Time
1288: Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
CE: 0.00
10:30 AM - 12:30 PM Central Time
1289: Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Location: Hall F1
Abstract Poster Presenter: Jida Jaffan, MA – The Hospital for Sick Children/ University of Toronto
CE: 0.00
10:30 AM - 12:30 PM Central Time
1290: Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-onset Systemic Lupus Erythematosus (cSLE)
1295: Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Location: Hall F1
Abstract Poster Presenter: Martha Rodriguez, MD – Riley Hospital For Children At Indiana University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1296: Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
1298: Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups
Location: Hall F1
Abstract Poster Presenter: Nellie Butler, BA – Children's Hospital of Philadelphia
CE: 0.00
10:30 AM - 12:30 PM Central Time
1299: Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Location: Hall F1
Abstract Poster Presenter: Rasha Elrefai, MD – Baylor College of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1300: International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
1303: Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases:a Two-sample Mendelian Randomization Study
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
CE: 0.00
10:30 AM - 12:30 PM Central Time
1304: The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1305: Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
CE: 0.00
10:30 AM - 12:30 PM Central Time
(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II
CE: 0.00
10:30 AM - 12:30 PM Central Time
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
1306: Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
1320: Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
1323: Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
1331: anti-beta-2-glycoprotein-1 Iga Antibodies Facilitate Macrophage Cholesterol Loading and Influence Coronary Atherosclerosis Progression in a Dose-dependent Manner in Rheumatoid Arthritis
1341: Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
CE: 0.00
10:30 AM - 12:30 PM Central Time
1343: Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
1346: Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
Location: Hall F1
Abstract Poster Presenter: YU Chen, MD, MSc, BA (she/her/hers) – 1. Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C.
CE: 0.00
10:30 AM - 12:30 PM Central Time
1342: The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
CE: 0.00
10:30 AM - 12:30 PM Central Time
1330: Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
(1347–1375) Rheumatoid Arthritis – Treatment Poster II
CE: 0.00
10:30 AM - 12:30 PM Central Time
Rheumatoid Arthritis – Treatment Poster II
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
1347: The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
1348: Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Location: Hall F1
Abstract Poster Presenter: AJ Fernandez, n/a – Eli Lilly and Company
CE: 0.00
10:30 AM - 12:30 PM Central Time
1349: Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study
Location: Hall F1
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1350: Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Location: Hall F1
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1351: Are Glucocorticoids Associated with Worse Overall Survival Among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
1353: Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
1354: Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Hongtao Jin, MD – The Second Hospital of Hebei Medical University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1355: Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
1359: Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Maya Khasho, MD – University of central florida
CE: 0.00
10:30 AM - 12:30 PM Central Time
1360: Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
1361: Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Location: Hall F1
Abstract Poster Presenter: Mingfang Sun, MD – Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1362: Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
1363: Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Location: Hall F1
Abstract Poster Presenter: NAOKI Kondo, MD, PhD – Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1364: Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
1365: Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
1366: Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
1371: Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
CE: 0.00
10:30 AM - 12:30 PM Central Time
1372: Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
CE: 0.00
10:30 AM - 12:30 PM Central Time
1373: Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
CE: 0.00
10:30 AM - 12:30 PM Central Time
1374: AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
1375: 86-96% of Rheumatoid Arthritis (RA) Patients with RA Who Have 0 or 1 Swollen Joint or Tender Joint but Are Classified as Moderate/high on RA Indices Have 1-9 Comorbidities Recognized on a Multidimensional Health Assessment Questionnaire (MDHAQ)
1391: Assessment of Anti-ssa/ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Location: Hall F1
Abstract Poster Presenter: Mala Masson, BA – NYU Langone Medical Center- Division of Rheumatology
CE: 0.00
10:30 AM - 12:30 PM Central Time
1392: Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
1381: Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
1398: Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
1394: Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
1396: Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Nevsun Inanc, MD (she/her/hers) – Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology
CE: 0.00
10:30 AM - 12:30 PM Central Time
1401: Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States
1402: Understanding Fatigue Through Patients' Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Saviana Gandolfo, MD – Rheumatology Unit, Ospedale del mare, Naples
CE: 0.00
10:30 AM - 12:30 PM Central Time
1379: Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Location: Hall F1
Abstract Poster Presenter: Biji T Kurien, PhD – Oklahoma Medical Research Foundation
CE: 0.00
10:30 AM - 12:30 PM Central Time
1387: Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
1386: Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II
CE: 0.00
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
1405: A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
1407: Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
CE: 0.00
10:30 AM - 12:30 PM Central Time
1408: When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
CE: 0.00
10:30 AM - 12:30 PM Central Time
1409: The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
1410: Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Location: Hall F1
Abstract Poster Presenter: Connor Vershel, MD – University of Texas at Houston
CE: 0.00
10:30 AM - 12:30 PM Central Time
1411: Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
1414: Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Location: Hall F1
Abstract Poster Presenter: Eugeniu Russu, MD, PhD – State Medical and Pharmaceutical University ”Nicolae Testemitanu”; "Timofei Mosneaga" Republican Clinical Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1415: The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1417: Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
Location: Hall F1
Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
CE: 0.00
10:30 AM - 12:30 PM Central Time
1418: Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
1419: Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1420: A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Isadora Small, n/a – The Latin School of Chicago
CE: 0.00
10:30 AM - 12:30 PM Central Time
1421: Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
Location: Hall F1
Abstract Poster Presenter: Lily Mikolajczak, BS – Georgetown University School of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1422: Assessment of Difficulties, Modifications and Use of Work Adaptations in Patients with Axial Spondyloarthritis: Validation of the Dificultax and Modal Questionnaires
1416: Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II
CE: 0.00
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II
Location: Hall F1
CE: 0.00
10:30 AM - 12:30 PM Central Time
1434: Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Location: Hall F1
Abstract Poster Presenter: Adam Mayer, MD – Hackensack University Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1435: Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
1436: Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Location: Hall F1
Abstract Poster Presenter: Devy Zisman, MD – Carmel Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1437: Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
1438: Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
1441: Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Location: Hall F1
Abstract Poster Presenter: Hongbin Li, MD – Affiliated Hospital of Inner Mongolia Medical University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1442: Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
1444: Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
1445: Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
Location: Hall F1
Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1446: Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
1447: Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
1449: Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Lianne S. Gensler, MD – University of California San Francisco
CE: 0.00
10:30 AM - 12:30 PM Central Time
1450: The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Location: Hall F1
Abstract Poster Presenter: Marc Schmalzing, MD – University Hospital Wuerzburg
CE: 0.00
10:30 AM - 12:30 PM Central Time
1451: Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
CE: 0.00
10:30 AM - 12:30 PM Central Time
1452: Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
1453: Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1454: Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1455: Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1456: Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1457: Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1458: Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1459: Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
1460: Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
1461: Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
1462: Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
1464: Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
1465: Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
1466: Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
1469: Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
1477: Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
Location: Hall F1
Abstract Poster Presenter: Beste Acar, MD – Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa
CE: 0.00
10:30 AM - 12:30 PM Central Time
1478: Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Bin zhou, MD – The First School of Clinical Medicine, Southern Medical University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1479: Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Location: Hall F1
Abstract Poster Presenter: Chen Chao, MD, MBA – Montefiore Medical Center/Albert Einstein College of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1480: Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
Location: Hall F1
Abstract Poster Presenter: Chen-Yu Lee, MD – Johns Hopkins University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1481: Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
1482: Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Location: Hall F1
Abstract Poster Presenter: Erik Cimé-Aké, n/a – Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department
CE: 0.00
10:30 AM - 12:30 PM Central Time
1483: Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
1486: Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Location: Hall F1
Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
CE: 0.00
10:30 AM - 12:30 PM Central Time
1487: Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
1493: Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
1496: Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
Location: Hall F1
Abstract Poster Presenter: Manikandan Gopal, DM – Christian Medical College Vellore
CE: 0.00
10:30 AM - 12:30 PM Central Time
1497: Acute Care Utilization in Patients with Antiphospholipid Syndrome And/or Systemic Lupus Erythematosus
1500: Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1501: Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes - Results from Real World Data
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1502: Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1503: Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
1504: High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
Location: Hall F1
Abstract Poster Presenter: Richard Oppong, PhD – NATIONAL INSTITUTES OF HEALTH
CE: 0.00
10:30 AM - 12:30 PM Central Time
1505: Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada
Location: Hall F1
Abstract Poster Presenter: Romy Kallas, MD, MS – Hospital for Special Surgery
CE: 0.00
10:30 AM - 12:30 PM Central Time
1506: Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
CE: 0.00
10:30 AM - 12:30 PM Central Time
1507: Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
CE: 0.00
10:30 AM - 12:30 PM Central Time
1508: Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Location: Hall F1
Abstract Poster Presenter: Sheila Serin, MD – Ochsner Clinic Foundation
CE: 0.00
10:30 AM - 12:30 PM Central Time
1509: Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
1510: Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Location: Hall F1
Abstract Poster Presenter: Sitian Zang, n/a – Department of Rheumatology and Immunology, Peking University People’s Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1511: Mental Health and Medical Burden: The Impact of Depression on Length of Stay in Lupus Patients
Location: Hall F1
Abstract Poster Presenter: Sophia Chang Stauffer, MPH – Mount Sinai Hospital, Sinai Urban Health Institute and Univ.of Illinois @ Chicago, Dept Medicine, Div. Endocrinology
CE: 0.00
10:30 AM - 12:30 PM Central Time
1512: anti-u1-rnp Antibody Positivity Is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Location: Hall F1
Abstract Poster Presenter: Takemichi Matsui, MD – Icahn School of Medicine at Mount Sinai
CE: 0.00
10:30 AM - 12:30 PM Central Time
1513: Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Location: Hall F1
Abstract Poster Presenter: Ufuoma Mamoh, MBChB – Medstar Georgetown University (Baltimore) Internal Medicine Residency
Abstract Poster Presenter: Yan Wang, n/a (she/her/hers) – Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
CE: 0.00
10:30 AM - 12:30 PM Central Time
1515: Machine Learning–defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Location: Hall F1
Abstract Poster Presenter: Yuke Hou, MD – Peking university
CE: 0.00
10:30 AM - 12:30 PM Central Time
1516: The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
1520: Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Bahtiyar Toz, MD – Zucker School of Medicine at Hofstra/ Northwell
CE: 0.00
10:30 AM - 12:30 PM Central Time
1521: Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Location: Hall F1
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1522: Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Location: Hall F1
Abstract Poster Presenter: Carlos Pena, MD – Jefferson Einstein Philadelphia
CE: 0.00
10:30 AM - 12:30 PM Central Time
1523: Genetic architecture and translational insights for SLE progression from preclinical stages
1529: Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
1530: The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Guillermo Pons-Estel, MD, PhD – Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina
CE: 0.00
10:30 AM - 12:30 PM Central Time
1531: Achieving Remission and Low Disease Activity with Belimumab versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
CE: 0.00
10:30 AM - 12:30 PM Central Time
1532: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
1536: Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Location: Hall F1
Abstract Poster Presenter: Aarat Patel, MD – GSK, US Medical Affairs
CE: 0.00
10:30 AM - 12:30 PM Central Time
1537: Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Melanie Hagen, MD (she/her/hers) – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
CE: 0.00
10:30 AM - 12:30 PM Central Time
1538: Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Location: Hall F1
Abstract Poster Presenter: Minoru Hasegawa, MD;PhD – Division of Medicine, University of Fukui
CE: 0.00
10:30 AM - 12:30 PM Central Time
1539: The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
1541: Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Location: Hall F1
Abstract Poster Presenter: Qizhi Yuan, PhD – Peking Union Medical College
CE: 0.00
10:30 AM - 12:30 PM Central Time
1542: Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-week Phase 3 Trial
1545: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
1552: Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
1555: Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
1556: Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
1558: Gastrointestinal Symptom Severity Is Associated with Worse Patient-reported Outcomes and Dietary Patterns in Systemic Sclerosis: A Single Center Prospective Study
1570: Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Location: Hall F1
Abstract Poster Presenter: Francesco Bonomi, MD – University Hospital Careggi, Florence
CE: 0.00
10:30 AM - 12:30 PM Central Time
1571: Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
1572: Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Tracy Frech, MD, MS – Vanderbilt University Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1573: Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival
Location: Hall F1
Abstract Poster Presenter: Katie van der Wouden, MD – Leiden University Medical Center and Amsterdam University Medical Center
CE: 0.00
10:30 AM - 12:30 PM Central Time
1574: A Rise in Serum KL-6 Levels Predicts Subsequent Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Keina Yomono, MD – Nippon Medical School
CE: 0.00
10:30 AM - 12:30 PM Central Time
1575: Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
CE: 0.00
10:30 AM - 12:30 PM Central Time
1576: Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
1577: Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Location: Hall F1
Abstract Poster Presenter: Luc Mouthon, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
CE: 0.00
10:30 AM - 12:30 PM Central Time
1578: Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
1579: Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
CE: 0.00
10:30 AM - 12:30 PM Central Time
1580: Lung Vasculature Quantification on Computed Tomography Predicts New Onset of Interstitial Lung Disease in Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
CE: 0.00
10:30 AM - 12:30 PM Central Time
1581: The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
1582: Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Location: Hall F1
Abstract Poster Presenter: Marissa Savoie, MD – Hospital for Special Surgery
CE: 0.00
10:30 AM - 12:30 PM Central Time
1583: Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
1610: Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
1598: Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
Location: Hall F1
Abstract Poster Presenter: Caterina Ricordi, MD – AUSL-IRCCS of Reggio Emilia and University of Modena and Reggio Emilia
CE: 0.00
10:30 AM - 12:30 PM Central Time
1609: A Multicenter Prospective Longitudinal Observational Study to Determine Safety of Extended Treatment with Rituximab in Maintaining Remission in Patients with ANCA Associated Vasculitis (AAV) - An Interim Analysis
Location: Hall F1
Abstract Poster Presenter: Ravi Kumar U, DM – Christian Medical College, Vellore, India
CE: 0.00
10:30 AM - 12:30 PM Central Time
1597: Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
1601: Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series
Location: Hall F1
Abstract Poster Presenter: Helen Au, MBBS – Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim
CE: 0.00
10:30 AM - 12:30 PM Central Time
1611: Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Yusuke Ushio, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
CE: 0.00
10:30 AM - 12:30 PM Central Time
1595: Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
1603: SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Location: Hall F1
Abstract Poster Presenter: Julia Foos, BA – University of Toledo College of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1596: GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
1605: Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Miriam Guerini, MBChB – IRCCS Policlinico San Matteo, University of Pavia
CE: 0.00
10:30 AM - 12:30 PM Central Time
1594: Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
1614: A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
1615: Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis
1617: Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Location: Hall F1
Abstract Poster Presenter: Erik Stone, MA – Global Healthy Living Foundation
CE: 0.00
10:30 AM - 12:30 PM Central Time
1618: Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
Location: Hall F1
Abstract Poster Presenter: Fatma Alibaz-Oner, MD – MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY
CE: 0.00
10:30 AM - 12:30 PM Central Time
1619: Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
1627: A Systematic Literature Review to Inform the 2025 EULAR Recommendations for Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Management of Disease Including Relapse and Complications
1628: Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
Location: Hall F1
Abstract Poster Presenter: Nuzhat Batool, MBBS – NYU Grossman Long Island School of Medicine
CE: 0.00
10:30 AM - 12:30 PM Central Time
1629: Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
1630: Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria
1637: Sleep Quality as a Modifier of the Relationship Between Physical Activity and Functional Limitation in Adults with or at High Risk of Knee Osteoarthritis
1642: The Impact of Secukinumab on Bone Density in Patients with Ankylosing Spondylitis: A 1-Year Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
CE: 0.00
10:30 AM - 12:30 PM Central Time
1643: Optimizing Analyses of Chair Stand Test Outcome Data in the Multicenter Osteoarthritis Study: Exploration of Approaches to Handling Missing and/or Skewed Data with Performance-based Function Measures
Location: Hall F1
Abstract Poster Presenter: Michael LaValley, PhD – Boston University School of Public Health
CE: 0.00
10:30 AM - 12:30 PM Central Time
1644: Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Misti Paudel, PhD, MPH – Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity
CE: 0.00
10:30 AM - 12:30 PM Central Time
1645: A Sex-modified Association Between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) Blood Concentration and Prevalent Arthritis Among Young and Middle-aged US Adults
1647: Clinical Phenotypes of Participants with Radiographic Osteoarthritis Attaining Patient Acceptable Symptom State in the Multicenter Osteoarthritis Study
1648: Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
Seminar Presenter: Peter Grayson, MD, MSc – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Seminar Presenter: Peter Grayson, MD, MSc – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Time-Independent Disease State Identification Defines Distinct Trajectories Determined by Localized vs Systemic Inflammation in Patients with Early Rheumatoid Arthritis
1680: Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
Location: S103
Presenting Author: Valeria Manfrè, MD – Division of Rheumatology, Department of Medicine, University of Udine, Italy; Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, WI
CE: 0.00
1:15 PM - 1:30 PM Central Time
1681: Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
1683: Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
1685: The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
1677: First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
1678: Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
1679: Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
1668: A Clinically Validated Assay for Rapid Determination of Type I and Type II Interferon Activity in Pediatric Inflammatory Diseases
Location: W183A-C
Presenting Author: Pui Lee, MD, PhD – Boston Children's Hospital
CE: 0.00
1:15 PM - 1:30 PM Central Time
1669: Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
1671: Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
Location: W183A-C
Presenting Author: Alexei Grom, MD – Cincinnati Children's Hospital Medical Center
CE: 0.00
2:00 PM - 2:15 PM Central Time
1672: Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren's Disease into adulthood
1662: Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
1665: Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
Location: S102
Presenting Author: Hanieh Akbari, MD – Jefferson Einstein Montgomery Medical Center
CE: 0.00
2:00 PM - 2:15 PM Central Time
1666: Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
Location: S102
Presenting Author: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
CE: 0.00
2:15 PM - 2:30 PM Central Time
1667: Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
1661: Artificial Intelligence Applied to Patient Reported Outcomes and Passive Physiologic Sensor Data Can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Abstract Moderator: Edward Schwarz, PhD – University of Rochester, Rochester, NY, USA
CE: 0.00
1:00 PM - 1:15 PM Central Time
1650: Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
Location: W192A-C
Presenting Author: Hannah Johnson, BS – University of Nebraska Medical Center
CE: 0.00
1:15 PM - 1:30 PM Central Time
1651: Compound Heterozygosity for the Ile692del and Val726Ala Pathogenic MEFV Variants and Elevated IL-18 (CHIVE-18 syndrome) Is Distinct from Familial Mediterranean Fever (FMF) and Includes a Pronounced Response to Interferon Stimulation in Myeloid Cell Populations
Panelist: Michael Weisman, MD – Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA
1717: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
1718: Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Location: S102
Presenting Author: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
CE: 0.00
3:45 PM - 4:00 PM Central Time
1719: Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
1720: Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Location: S102
Presenting Author: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
CE: 0.00
4:15 PM - 4:30 PM Central Time
1721: Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Abstract Moderator: Sibel Aydin, MD – University of Ottawa - Ottawa
CE: 0.00
3:00 PM - 3:15 PM Central Time
1710: Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
1712: Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
1715: Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Location: S103
Presenting Author: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
CE: 0.00
3:00 PM - 4:30 PM Central Time
27M63: Abstracts: Healthcare Disparities in Rheumatology (1704–1709)
1706: Overcoming Barriers to ANA Testing in Pediatric Populations in Africa
Location: S105
Presenting Author: Ekemini Ogbu, MD, MSc – Cincinnati Children's Hospital Medical Center
CE: 0.00
3:45 PM - 4:00 PM Central Time
1707: Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Location: S105
Presenting Author: Soziema Salia, MD, MPH – MedStar Health Georgetown University (Baltimore) Internal Medicine Program
CE: 0.00
4:00 PM - 4:15 PM Central Time
1708: Assessing Social Determinants of Health Using PRAPARE in a Rheumatology Patient Navigator Program for Underserved Brooklyn Communities
1691: Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
Location: W192A-C
Presenting Author: Andrea Gutierrez, BS – University of Texas Southwestern Medical School
CE: 0.00
3:30 PM - 4:15 PM Central Time
IT8: Discover a Treatment Option for Macrophage Activation Syndrome (MAS)
27M70: Stats Bootcamp 2: Methods for Analyzing Groupings that Cannot be Directly Observed and Measured: An Introduction to Latent Structures and Latent Variable Models
27M70: Stats Bootcamp 2: Methods for Analyzing Groupings that Cannot be Directly Observed and Measured: An Introduction to Latent Structures and Latent Variable Models